Leveraging Morphological Profiling for Mechanistic Elucidation of Metal-Based Anticancer Compounds

Area of Science:

• Metallotherapeutics
• Chemical Biology
• Drug Discovery

Background:

• Metallodrug development faces challenges due to complex reactivity and unknown molecular targets.
• Phenotypic drug profiling has advanced anticancer therapies but is underutilized for metal-based agents.

Purpose of the Study:

• To apply morphological profiling to a metal-containing compound library for mechanism elucidation.
• To identify novel metallodrug candidates without predefined molecular targets.

Main Methods:

• Utilized morphological profiling on a diverse library of metal-containing compounds.
• Validated the strategy with clinically approved anticancer therapeutics (oxaliplatin, cisplatin, carboplatin, BOLD-100).
• Combined cytotoxicity, selectivity, and morphological profiling to identify novel compounds.

Main Results:

• Morphological profiling differentiated mechanisms of established metallodrugs.
• Identified a novel ruthenium 2-(2-pyridyl)-benzimidazole series with anticancer potential.
• These compounds induced mitochondrial morphology changes, increased reactive oxygen species, and depolarized mitochondrial membranes.

Conclusions:

• Morphological profiling is a viable strategy for understanding metallodrug mechanisms of action.
• This approach accelerates the identification and rational development of promising metallotherapeutics.
• It effectively addresses challenges in metallodrug discovery by focusing on phenotypic effects.